Lexicon Pharma (LXRX) Tops Q3 EPS by 7c, Miss on Revenues
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.04 -0.49%
Revenue Growth %: -78.9%
Financial Fact:
Interest expense: -1.65M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Revenue Growth %: -78.9%
Financial Fact:
Interest expense: -1.65M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.29), $0.07 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $26.94 million versus the consensus estimate of $27.96 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Evercore lifts Ciena rating on AI-driven optical networking boom
- CMS targets 15% Medicare lab fee cuts, putting DGX and LH revenue at risk
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
